|
1
|
Dong L, Xue L, Cheng W, Tang J, Ran J and
Li Y: Comprehensive survival analysis of oral squamous cell
carcinoma patients undergoing initial radical surgery. BMC Oral
Health. 24(919)2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49.
2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pekarek L, Garrido-Gil MJ, Sánchez-Cendra
A, Cassinello J, Pekarek T, Fraile-Martinez O, García-Montero C,
Lopez-Gonzalez L, Rios-Parra A, Álvarez-Mon M, et al: Emerging
histological and serological biomarkers in oral squamous cell
carcinoma: Applications in diagnosis, prognosis evaluation and
personalized therapeutics (Review). Oncol Rep.
50(213)2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S,
Nice EC, Tang J and Huang C: Oral squamous cell carcinomas: State
of the field and emerging directions. Int J Oral Sci.
15(44)2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Deng H, Sambrook PJ and Logan RM: The
treatment of oral cancer: An overview for dental professionals.
Aust Dent J. 56:244–252. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Eskander A, Dziegielewski PT, Patel MR,
Jethwa AR, Pai PS, Silver NL, Sajisevi M, Sanabria A and Doweck I:
Oral cavity cancer surgical and nodal management: A review from the
american head and neck society. JAMA Otolaryngol Head Neck Surg.
150:172–178. 2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Fu JY, Yue XH, Dong MJ, Li J and Zhang CP:
Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin,
and fluorouracil in patients with oral cavity cancer. Cancer Med.
12:2417–2426. 2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Atashi F, Vahed N, Emamverdizadeh P,
Fattahi S and Paya L: Drug resistance against 5-fluorouracil and
cisplatin in the treatment of head and neck squamous cell
carcinoma: A systematic review. J Dent Res Dent Clin Dent
Prospects. 15:219–225. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jiang Q, Xiao J, Hsieh YC, Kumar NL, Han
L, Zou Y and Li H: The role of the PI3K/Akt/mTOR axis in head and
neck squamous cell carcinoma. Biomedicines. 12(1610)2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Liu L, Chen J, Cai X, Yao Z and Huang J:
Progress in targeted therapeutic drugs for oral squamous cell
carcinoma. Surg Oncol. 31:90–97. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Xu MJ, Johnson DE and Grandis JR:
EGFR-targeted therapies in the post-genomic era. Cancer Metastasis
Rev. 36:463–473. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ferreira DM, Neves TJ, Lima LGCA, Alves FA
and Begnami MD: Prognostic implications of the phosphatidylinositol
3-kinase/Akt signaling pathway in oral squamous cell carcinoma:
Overexpression of p-mTOR indicates an adverse prognosis. Applied
Cancer Research. 37(41)2017.
|
|
13
|
de Kort WWB, Spelier S, Devriese LA, van
Es RJJ and Willems SM: Predictive value of
EGFR-PI3K-AKT-mTOR-pathway inhibitor biomarkers for head and neck
squamous cell carcinoma: A systematic review. Mol Diagn Ther.
25:123–136. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Satgunaseelan L, Porazinski S, Strbenac D,
Istadi A, Willet C, Chew T, Sadsad R, Palme CE, Lee JH, Boyer M, et
al: Oral squamous cell carcinoma in young patients show higher
rates of EGFR amplification: Implications for novel personalized
therapy. Front Oncol. 11(750852)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Argiris A, Kotsakis AP, Hoang T, Worden
FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR Jr, Chen
HX, Grandis JR, et al: Cetuximab and bevacizumab: Preclinical data
and phase II trial in recurrent or metastatic squamous cell
carcinoma of the head and neck. Ann Oncol. 24:220–225.
2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chen Q, Chao R, Chen H, Hou X, Yan H, Zhou
S, Peng W and Xu A: Antitumor and neurotoxic effects of novel
harmine derivatives and structure-activity relationship analysis.
Int J Cancer. 114:675–682. 2005.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang L, Li D and Yu S: Pharmacological
effects of harmine and its derivatives: A review. Arch Pharm Res.
43:1259–1275. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Jalali A, Dabaghian F and Zarshenas MM:
Alkaloids of peganum harmala: Anticancer biomarkers with promising
outcomes. Curr Pharm Des. 27:185–196. 2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hu Y, Yu X, Yang L, Xue G, Wei Q, Han Z
and Chen H: Research progress on the antitumor effects of harmine.
Front Oncol. 14(1382142)2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tarpley M, Oladapo HO, Strepay D, Caligan
TB, Chdid L, Shehata H, Roques JR, Thomas R, Laudeman CP, Onyenwoke
RU, et al: Identification of harmine and β-carboline analogs from a
high-throughput screen of an approved drug collection; profiling as
differential inhibitors of DYRK1A and monoamine oxidase A and for
in vitro and in vivo anti-cancer studies. Eur J Pharm Sci.
162(105821)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Nafie E, Lolarga J, Lam B, Guo J,
Abdollahzadeh E, Rodriguez S, Glackin C and Liu J: Harmine inhibits
breast cancer cell migration and invasion by inducing the
degradation of Twist1. PLoS One. 16(e0247652)2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhang P, Huang CR, Wang W, Zhang XK, Chen
JJ, Wang JJ, Lin C and Jiang JW: Harmine hydrochloride triggers G2
phase arrest and apoptosis in MGC-803 cells and SMMC-7721 cells by
upregulating p21, activating caspase-8/Bid, and downregulating
ERK/Bad pathway. Phytother Res. 30:31–40. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Tan B, Li Y, Zhao Q, Fan L and Zhang M:
The impact of Harmine hydrochloride on growth, apoptosis and
migration, invasion of gastric cancer cells. Pathol Res Pract.
216(152995)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Xiong Y, Connolly T, Futcher B and Beach
D: Human D-type cyclin. Cell. 65:691–699. 1991.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Goel S, Bergholz JS and Zhao JJ: Targeting
CDK4 and CDK6 in cancer. Nat Rev Cancer. 22:356–372.
2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Gudas JM, Payton M, Thukral S, Chen E,
Bass M, Robinson MO and Coats S: Cyclin E2, a novel G1 cyclin that
binds Cdk2 and is aberrantly expressed in human cancers. Mol Cell
Biol. 19:612–622. 1999.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Sherr CJ and Roberts JM: Inhibitors of
mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1149–1163.
1995.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Abukhdeir AM and Park BH: P21 and p27:
Roles in carcinogenesis and drug resistance. Expert Rev Mol Med.
10(e19)2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kim GD: Harmine hydrochloride triggers
G2/M cell cycle arrest and apoptosis in HCT116 cells through ERK
and PI3K/AKT/mTOR signaling pathways. Prev Nutr Food Sci.
26:445–452. 2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ock CW and Kim GD: Harmine hydrochloride
mediates the induction of G2/M Cell cycle arrest in breast cancer
cells by regulating the MAPKs and AKT/FOXO3a signaling pathways.
Molecules. 26(6714)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ling Z, Cheng B and Tao X:
Epithelial-to-mesenchymal transition in oral squamous cell
carcinoma: Challenges and opportunities. Int J Cancer.
148:1548–1561. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yin SY, Wei WC, Jian FY and Yang NS:
Therapeutic applications of herbal medicines for cancer patients.
Evid Based Complement Alternat Med. 2013(302426)2013.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kim GD: Harmine hydrochloride induces G2/M
cell cycle arrest and apoptosis in SK-Hep1 hepatocellular carcinoma
cells by regulating mitogen-activated protein kinases and the
PI3K/AKT pathway. Prev Nutr Food Sci. 28:436–443. 2023.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lossi L: The concept of intrinsic versus
extrinsic apoptosis. Biochem J. 479:357–384. 2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Gottlieb E, Armour SM, Harris MH and
Thompson CB: Mitochondrial membrane potential regulates matrix
configuration and cytochrome C release during apoptosis. Cell Death
Differ. 10:709–717. 2003.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Kharbanda S, Pandey P, Schofield L,
Israels S, Roncinske R, Yoshida K, Bharti A, Yuan ZM, Saxena S, et
al: Role for Bcl-xL as an inhibitor of cytosolic cytochrome C
accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci U
S A. 94:6939–6942. 1997.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Li M, Wang D, He J, Chen L and Li H:
Bcl-X(L): A multifunctional anti-apoptotic protein. Pharmacol Res.
151(104547)2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wada T and Penninger JM: Mitogen-activated
protein kinases in apoptosis regulation. Oncogene. 23:2838–2849.
2004.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Cheng Y, Chen J, Shi Y, Fang X and Tang Z:
MAPK signaling pathway in oral squamous cell carcinoma: Biological
function and targeted therapy. Cancers (Basel).
14(4625)2022.PubMed/NCBI View Article : Google Scholar
|
